Moderna and Merck Shares Rise on Results From Experimental mRNA Cancer Vaccine
Moderna and Merck have reported encouraging clinical trial results for their experimental mRNA cancer vaccine, saying melanoma patients receiving the treatment alongside existing immunotherapy had significantly better survival outcomes.